Renal & Urology News recently reported on the summary of the Human epidermal growth factor receptor 2 (HER2) breast cancer gene from a paper completed by Mayo Clinic’s John Cheville, M.D. and his colleagues. According to the paper, HER2 amplification is more frequent in micropapillary urothelial carcinoma than in typical urothelial carcinoma, and patients with micropapillary carcinoma who have HER2 amplification have worse cancer-specific survival than those who do not.
Dr. Cheville’s group reached this conclusion after reviewing pathologic material and data from persons undergoing cystectomy at the facility from 1980 to 2008. They identified amplification of HER2 (referred to as ERBB2 in the study) in 9 of 61 micropapillary carcinomas (15%) compared with 9 of 100 urothelial carcinomas (9%).
According to a statement from Dr. Cheville, “These findings show it is critical for pathologists to recognize this type of bladder cancer and for providers to order the appropriate tests.”